TYSABRI J Code: J2323

Drug & Product Overview

HCPCS Descriptor Injection, natalizumab, 1 mg

HCPCS Added Date January 1, 2008

Manufacturer Biogen

Route of Administration Intravenous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection

About TYSABRI

Tysabri is a medication aligned to the HCPCS J Code: J2323 for billing, pricing, and reimbursement purposes in the United States. It is a Neurology drug administered via the intravenous route and manufactured by Biogen.

According to CMS Drug Use Information: Natalizumab is used to treat multiple sclerosis-MS. It is not a cure for MS, but it is thought to help by preventing your immune system from attacking the nerves in your brain and spinal cord. It helps decrease the number of episodes of worsening symptoms and may prevent or delay disability. Natalizumab is also used to treat a bowel condition called Crohn's disease (CD). It is not a cure for CD, but it is thought to work by preventing your immune system from causing inflammation/swelling within your bowels. Natalizumab is a protein called a monoclonal antibody. This monograph is about the following natalizumab products: natalizumab and natalizumab-sztn.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
64406-0008-01	Tysabri	Biogen Inc.	300	300 MG / 15 ML

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

TYSABRI Pricing & Reimbursement

J2323 Private Payer Reimbursement

$24.48 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

Natalizumab Biosimilar Information:

TYSABRI Approval Date: November 23, 2004

Product Name	HCPCS Code	Active Ingredient	BLA Type
Tysabri	J2323	Natalizumab	351(a) Originator Product
Tyruko	Q5134	Natalizumab	351(k) Biosimilar

TYSABRI Claims Performance

Claims from Jan 2026 – Aug 2026

Claim Denial Rate 17.64%

Avg. Days to File 7.4days

Avg. Days to Pay 22.8days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore J2323 claims analytics on FocalPoint →

TYSABRI CPT Administration Codes

CPT Code	Description
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)

JW / JZ modifiers apply

CMS has identified Tysabri (J2323) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

TYSABRI Medically Unlikely Edits (MUE)

The most billing units of J2323 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 1 mg.

Practitioner Office & Hospital Outpatient

300 units / day

= 300 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

TYSABRI Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Crohn's Disease Multiple Sclerosis

Drug Class

Integrin Receptor Antagonist [EPC]Integrin Receptor Antagonists [MoA]

Frequently Asked Questions

Is there an available Tysabri billing and coding guide?

Billing and coding information for TYSABRI can be found through Biogen. Visit Here →

Are there any available Tysabri patient assistance programs?

TYSABRI patient assistance information can be found through Biogen. Visit Here →

Where can I find Tysabri prescribing information?

TYSABRI prescribing information can be found at the link below: Visit Here →

Where can I find Tysabri side effect information?

Information regarding TYSABRI's side effects can be found at MedlinePlus Visit Here →

Does billing TYSABRI require JZ/JW wastage modifiers?

CMS has identified TYSABRI(J2323) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.